Share chart Revolution Medicines, Inc.
About Revolution Medicines, Inc.
Revolution Medicines, Inc., компания, занимающаяся прецизионной онкологией, специализируется на разработке методов лечения, направленных на подавление мишеней, в первую очередь, в сигнальных путях RAS и mTOR. Основным кандидатом на продукт компании является RMC-4630, ингибитор SHP2, который находится в фазе 1b> F2 исследования для лечения РАС-зависимых опухолей. Его продукты на доклинической стадии включают мутантные белки RAS; SOS1, белок, который превращает RAS (OFF) в RAS (ON) в клетках; и RMC-5552, ингибитор mTORC1. Revolution Medicines, Inc. заключила соглашение о сотрудничестве с Санофи в области исследования и разработки ингибиторов SHP2. Компания была основана в 2014 году, ее штаб-квартира находится в Редвуд-Сити, штат Калифорния.
Main settings
Grade
Underestimation
Title | Value | Grade |
P/S | 282.39 | 1 |
P/BV | 3.24 | 5 |
P/E | 0 | 0 |
Efficiency
Title | Value | Grade |
ROA | -25.98 | 0 |
ROE | -29.33 | 0 |
ROIC | -30.41 | 0 |
Dividends
Title | Value | Grade |
Dividend yield | 0 | 0 |
DSI | 0 | 0 |
Average dividend growth | 0 | 0 |
Debt
Title | Value | Grade |
Debt/EBITDA | -0.2306 | 10 |
Debt/Ratio | 0.0531 | 10 |
Debt/Equity | 0.1294 | 10 |
Growth impulse
Title | Value | Grade |
Yield Revenue, % | -76.84 | 0 |
Yield Ebitda, % | 442.88 | 10 |
Yield EPS, % | 81.6 | 9 |
Prices
Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
Yesterday | 41.11 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
Week | 41.09 $ | 0 $ | 0 $ | 0.05 % | 0 % | 0 % |
Month | 38.8 $ | 41.11 $ | 41.11 $ | 5.95 % | 0 % | 0 % |
Three month | 35.12 $ | 35.72 $ | 41.98 $ | 17.06 % | 0 % | 0 % |
Half a year | 42.32 $ | 31.13 $ | 44.25 $ | -2.86 % | 0 % | 0 % |
Year | 43.59 $ | 31.13 $ | 60.6 $ | -5.69 % | 0 % | 0 % |
3 years | 20.01 $ | 17.46 $ | 60.6 $ | 105.45 % | 0 % | 0 % |
5 years | 30.96 $ | 14.99 $ | 60.6 $ | 32.78 % | 0 % | 0 % |
10 years | 14.99 $ | 14.99 $ | 60.6 $ | 274.25 % | 0 % | 0 % |
Year to date | 40.73 $ | 31.13 $ | 44.42 $ | 0.93 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
Future Tech ETF | 0.73744 | 479.5 | 0.35 |
Principal Healthcare Innovators ETF | 0.73744 | -3.92 | 0.35 |
iShares Morningstar Small-Cap Value ETF | 0.17568 | 175.74 | 0.06 |
iShares Morningstar Small-Cap ETF | 0.13634 | 301.34 | 0.25 |
iShares Morningstar Small-Cap Growth ETF | 0.09999 | 570.49 | 0.06 |
0.38 | 304.63 | 0.21 |
---|
Similar companies
Company management
Head | Job title | Payment | Year of birth |
Mr. Jack Anders | Chief Financial Officer | 544.8k | 1977 (48 years) |
Mr. Walter Reiher Ph.D. | Chief Information Officer | N/A | |
Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | N/A | |
Dr. Mark A. Goldsmith Ph.D. | CEO, President & Chairman | 1.05M | 1962 (63 years) |
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | President of Research & Development | 779k | 1961 (64 years) |
Ms. Margaret A. Horn J.D. | Chief Operating Officer | 775.6k | 1963 (62 years) |
Ms. Xiaolin Wang | Executive Vice President of Development | 604.1k | 1971 (54 years) |
Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | N/A | |
Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | N/A | 1981 (44 years) |
Ms. Jan Smith Ph.D. | Chief Scientific Officer | N/A |
About company
Website: https://www.revmed.com